Novartis, PTC Therapeutics

Novartis in up to $2.9 billion licensing deal for PTC Therapeutics Huntington's disease drug
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological disorder called Huntington's disease, sending the U.S.-based biotech's shares up about 14% on Monday.
PTC Therapeutics Stock Soars on Novartis Licensing Agreement
Key Takeaways Shares of PTC Therapeutics soared Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and collaboration deal with Novartis.The deal gives Novartis global development,
Novartis wagers billions of dollars on PTC Huntington’s drug
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly 250-person study that should produce results next year.
Novartis signs licensing deal worth up to $2.9B with PTC Therapeutics
The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.
Novartis to pay $1 billion upfront to license Huntington’s drug from PTC
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC Therapeutics.
Novartis, PTC Ink Up-to-$2.9B Huntington’s Disease Collaboration
Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license and collaboration agreement.
PTC Therapeutics enters global license, collaboration agreement with Novartis
PTC Therapeutics (PTCT) announced the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals
PTC Therapeutics signs up to $2.9 billion licensing deal with Novartis
PTC Therapeutics has signed an up to $2.9 billion licensing deal with Novartis AG for the U.S. company's experimental drug for a rare neurological disorder, sending its shares up 20% in premarket trading on Monday.
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
PTC Therapeutics (PTCT) signed a licensing deal with Novartis (NVS) unit Novartis Pharmaceuticals worth up to $2.9 billion for PTC518, its candidate treatment for Huntington's disease, the companies said in separate Monday statements.
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Novartis will pay PTC Therapeutics up to $2.9 billion in a licensing deal for its Huntington's treatment. PTC Therapeutics stock surged.
Novartis cannot block generic of best-selling heart drug, US appeals court says
Novartis failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals' proposed generic of Novartis' ...
Yahoo Finance7h
Why Novartis (NVS) is a Top Growth Stock for the Long-Term
Switzerland-based Novartis has one of the strongest and broadest portfolios of varied drugs that has enabled it to maintain its dominant position as a top pharma company over the years. It continues ...
FierceBiotech2d
Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Novartis downgraded to Reduce from Hold at HSBC
HSBC analyst Rajesh Kumar downgraded Novartis (NVS) to Reduce from Hold with a price target of CHF 82, down from CHF 95. The firm calls the ...
Novartis Canada awards more than $680,000 to community-based programs aimed at advancing health equity
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the three recipients of its inaugural Health Equity ...
FierceBiotech13d
Novartis 'took data to heart' before slimming clinical pipeline by 40%, says CEO
Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...
Fmr LLC Boosts Stake in Novartis AG (NYSE:NVS)
Fmr LLC grew its position in shares of Novartis AG (NYSE:NVS – Free Report) by 5.5% during the 3rd quarter, Holdings ...
Novartis and Olema expand alliance with $250m to boost breast cancer trials
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.